Seagen (SGEN) Receives a Buy from SVB Securities

SVB Securities analyst Andrew Berens reiterated a Buy rating on Seagen (SGENResearch Report) on November 10 and set a price target of $112.00. The company’s shares closed last Friday at $132.91.

Berens covers the Healthcare sector, focusing on stocks such as AVEO Pharma, Seagen, and Merus. According to TipRanks, Berens has an average return of 3.9% and a 46.50% success rate on recommended stocks.

In addition to SVB Securities, Seagen also received a Buy from JMP Securities’s Reni Benjamin in a report issued on November 2. However, on October 31, Stifel Nicolaus maintained a Hold rating on Seagen (NASDAQ: SGEN).

See Insiders’ Hot Stocks on TipRanks >>

SGEN market cap is currently $24.68B and has a P/E ratio of -38.39.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Washington-based Seagen, Inc. is a biotechnology company, which is focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev.

Read More on SGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More